您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Adenosine-5'-diphosphate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Adenosine-5'-diphosphate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Adenosine-5'-diphosphate图片
CAS NO:58-64-0
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议

产品介绍

化学性质

StorageStore at -20°C
M.Wt427.2
Cas No.58-64-0
FormulaC10H15N5O10P2
SynonymsAdenosine Pyrophosphate,ADP,5′-ADP
Solubility≥21.35 mg/mL in DMSO with gentle warming; insoluble in EtOH; ≥24.85 mg/mL in H2O
Chemical Nameadenosine 5'-(trihydrogen diphosphate)
Canonical SMILESO[C@H]1[C@H](N2C=NC3=C2N=CN=C3N)O[C@H](COP(OP(O)(O)=O)(O)=O)[C@H]1O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 67 nM for P2X2/3

Adenosine-5'-diphosphate is an agonist of purinergic receptors.

Purinergic receptors, also known as purinoceptors, are a family of plasma membrane molecules that are found in almost all mammalian tissues. Within the field of purinergic signalling, these receptors have been implicated in learning and memory, locomotor and feeding behavior, and sleep. More specifically, purinergic receptors are involved in several cellular functions, such as proliferation and migration of neural stem cells, vascular reactivity, apoptosis and cytokine secretion.

In vitro: Adenosine 5'-diphosphate (ADP) is an adenine nucleotide having two phosphate groups esterified to the sugar moiety at the 5’ position. ADP is formed through dephosphorylation of adenosine 5’-triphosphate (ATP) by ATPases and can be converted back to ATP by ATP synthases. ADP can also be metabolized to adenosine 5’-monophosphate (AMP) and 2’-deoxyadenosine 5’-diphosphate (dADP). ADP can modulate several receptors, such as activating certain purinergic receptors and inhibiting others, inhibiting rat ecto-5’nucleotidase (Ki = 0.91 nM), as well as regulating the phosphorylation status of AMP-activated protein kinase [1, 2].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

References:
1.  Azran, S.,Frster, D.,Danino, O., et al. Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. J. Med. Chem. 56(12), 4938-4952 (2013).
2.  Jarvis, M.F.,Bianchi, B.,Uchic, J.T., et al. [3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors. Journal of Pharmacology and Experimental Therapeutics 310(1), 407-416 (2004).